Mark R. Bray

4.2k total citations
65 papers, 2.7k citations indexed

About

Mark R. Bray is a scholar working on Cell Biology, Molecular Biology and Oncology. According to data from OpenAlex, Mark R. Bray has authored 65 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cell Biology, 26 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in Mark R. Bray's work include Microtubule and mitosis dynamics (29 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer-related Molecular Pathways (11 papers). Mark R. Bray is often cited by papers focused on Microtubule and mitosis dynamics (29 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer-related Molecular Pathways (11 papers). Mark R. Bray collaborates with scholars based in Canada, United States and Hong Kong. Mark R. Bray's co-authors include Tak W. Mak, Jacqueline M. Mason, Graham C. Fletcher, Bryan E. Snow, Anthony J. Clarke, Kelsie L. Thu, Carmen Dominguez‐Brauer, Heiko Blaser, Robert J. Deeth and Dennis J. Slamon and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mark R. Bray

64 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark R. Bray Canada	27	1.6k	754	728	345	250	65	2.7k
Ilya G. Serebriiskii United States	33	2.5k 1.6×	1.0k 1.3×	730 1.0×	488 1.4×	346 1.4×	97	3.8k
Joshua A. McCarroll Australia	30	2.1k 1.3×	1.3k 1.7×	638 0.9×	581 1.7×	206 0.8×	61	4.0k
Rosa Angela Cardone Italy	32	2.2k 1.4×	611 0.8×	422 0.6×	808 2.3×	385 1.5×	72	3.5k
Christine Pirker Austria	31	1.4k 0.9×	1.0k 1.4×	188 0.3×	448 1.3×	518 2.1×	92	3.0k
Oliver von Ahsen Germany	24	1.7k 1.1×	832 1.1×	232 0.3×	567 1.6×	362 1.4×	52	2.8k
Rodney B. Luwor Australia	32	2.0k 1.3×	1.5k 1.9×	248 0.3×	867 2.5×	428 1.7×	95	3.7k
Darrin D. Stuart United States	25	1.7k 1.1×	819 1.1×	185 0.3×	241 0.7×	225 0.9×	50	2.3k
Linda H. Malkas United States	29	2.3k 1.4×	866 1.1×	197 0.3×	368 1.1×	100 0.4×	95	2.8k
Rüdiger Woscholski United Kingdom	30	3.0k 1.9×	412 0.5×	1.0k 1.4×	210 0.6×	108 0.4×	74	4.1k
Mårten Fryknäs Sweden	27	1.7k 1.1×	799 1.1×	224 0.3×	478 1.4×	137 0.5×	77	2.7k

Countries citing papers authored by Mark R. Bray

Since Specialization

Citations

This map shows the geographic impact of Mark R. Bray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Bray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Bray more than expected).

Fields of papers citing papers by Mark R. Bray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Bray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Bray. The network helps show where Mark R. Bray may publish in the future.

Co-authorship network of co-authors of Mark R. Bray

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Bray. A scholar is included among the top collaborators of Mark R. Bray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Bray. Mark R. Bray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Horace H.Y., Alice S.T. Wong, Grace H.W. Cheng, et al.. (2024). Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma. Clinical Cancer Research. 30(17). 3904–3918. 2 indexed citations

Murphy, Tracy, Jacqueline M. Mason, Brian Leber, et al.. (2023). Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. 38(3). 502–512. 11 indexed citations

Chan, Cerise Yuen‐Ki, David Kung‐Chun Chiu, Vincent Wai‐Hin Yuen, et al.. (2022). CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proceedings of the National Academy of Sciences. 119(32). e2119514119–e2119514119. 38 indexed citations

Soria‐Bretones, Isabel, Kelsie L. Thu, Jennifer Silvester, et al.. (2022). The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER ⁺ breast cancer with mitotic aberrations. Science Advances. 8(36). eabq4293–eabq4293. 26 indexed citations

Veitch, Zachary, David W. Cescon, Graham C. Fletcher, et al.. (2019). Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. British Journal of Cancer. 121(4). 318–324. 45 indexed citations

Szymiczek, Agata, Michele Carbone, Sandra Pastorino, et al.. (2017). Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. Oncogene. 36(46). 6501–6507. 20 indexed citations

Cescon, David W., Aaron R. Hansen, Albiruni Ryan Abdul Razak, et al.. (2017). Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS2619–TPS2619. 4 indexed citations

Yee, Karen, David W. Hedley, Sue Chow, et al.. (2016). A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Investigational New Drugs. 34(5). 614–624. 27 indexed citations

Dominguez‐Brauer, Carmen, Kelsie L. Thu, Jacqueline M. Mason, et al.. (2015). Targeting Mitosis in Cancer: Emerging Strategies. Molecular Cell. 60(4). 524–536. 365 indexed citations

10.

Diamond, Jennifer R., S. Gail Eckhardt, Aik Choon Tan, et al.. (2012). Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. Clinical Cancer Research. 19(1). 291–303. 39 indexed citations

11.

Matulonis, Ursula A., Julie Lee, William P. Tew, et al.. (2012). ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. European Journal of Cancer. 49(1). 121–131. 39 indexed citations

12.

Fletcher, Graham C., Richard D. Brokx, Todd Hembrough, et al.. (2010). ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action. Molecular Cancer Therapeutics. 10(1). 126–137. 109 indexed citations

13.

Diamond, Jennifer R., Bruno R. Bastos, Ryan J. Hansen, et al.. (2010). Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(4). 849–860. 57 indexed citations

14.

Kim, Raymond H., Malte Peters, Wei Shi, et al.. (2005). DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 7(3). 263–273. 473 indexed citations

15.

Anandan, Sampath‐Kumar, et al.. (2005). Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(8). 1969–1972. 29 indexed citations

16.

Wang, Judy, Raymond M. Reilly, Paul Chen, et al.. (2002). Fusion of the C _H 1 Domain of IgG ₁ to Epidermal Growth Factor (EGF) Prolongs its Retention in the Blood but Does Not Increase Tumor Uptake. Cancer Biotherapy and Radiopharmaceuticals. 17(6). 665–671. 3 indexed citations

17.

Bray, Mark R., et al.. (2001). Probing the surface of eukaryotic cells using combinatorial toxin libraries. Current Biology. 11(9). 697–701. 5 indexed citations

18.

Bray, Mark R., Neil R. Gilkes, Douglas G. Kilburn, et al.. (1996). Probing the role of tryptophan residues in a cellulose‐binding domain by chemical modification. Protein Science. 5(11). 2311–2318. 46 indexed citations

19.

Bray, Mark R., et al.. (1994). Quantitation of Tryptophan and Tyrosine Residues in Proteins by Fourth-Derivative Spectroscopy. Analytical Biochemistry. 221(2). 278–284. 20 indexed citations

20.

Bray, Mark R. & Anthony J. Clarke. (1990). Essential carboxy groups in xylanase A. Biochemical Journal. 270(1). 91–96. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact